Atlas Venture Opportunity Fund II, L.P. — SEC Form 4 filings

SEC reporting owner CIK 1885327. 6 Form 4 filings on record with FilingPulse; latest filed 2025-02-10.

Transaction summary — filings shown

Covers all 6 filings on record, filed 2024-01-25 to 2025-02-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Dyne Therapeutics, Inc. (DYN)10% owner326 legs · 1,355,161 sh · $32,365,030
Disc Medicine, Inc. (IRON)10% owner13 legs · 150,000 sh · $10,147,500
Sionna Therapeutics, Inc. (SION)10% owner11 leg · 60,000 sh · $1,080,0007
Korro Bio, Inc. (KRRO)10% owner11 leg · 17,857 sh · $999,992

Form 4 filings — Atlas Venture Opportunity Fund II, L.P.

FiledFormIssuerReported transactionsSource
2025-02-104Sionna Therapeutics, Inc. (SION)
jointly with Atlas Venture Fund XI, L.P., Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
Conversion (C): 2,886,293 · Conversion (C): 747,727 · Purchase (P): 60,000 @ $18 · Conversion (C): 1,051,051 (derivative) @ $0 · Conversion (C): 1,806,317 (derivative) @ $0 · Conversion (C): 1,298,332 (derivative) @ $0 · +2 moreEDGAR
2024-04-234Korro Bio, Inc. (KRRO)
jointly with Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
Purchase (P): 17,857 @ $56EDGAR
2024-03-054Dyne Therapeutics, Inc. (DYN)
jointly with Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
Sale (S): 29,435 @ $30.05 · Sale (S): 17,099 @ $30.05EDGAR
2024-02-284Dyne Therapeutics, Inc. (DYN)
jointly with Atlas Venture Fund XI, L.P., Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
Sale (S): 136,312 @ $23.59 · Sale (S): 64,783 @ $23.98 · Sale (S): 20,205 @ $23.59 · Sale (S): 9,603 @ $23.98 · Sale (S): 11,736 @ $23.59 · Sale (S): 5,580 @ $23.98 · +12 moreEDGAR
2024-02-234Dyne Therapeutics, Inc. (DYN)
jointly with Atlas Venture Fund XI, L.P., Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
Sale (S): 149,337 @ $22.44 · Sale (S): 35,164 @ $23.14 · Sale (S): 119,360 @ $22.66 · Sale (S): 159,542 @ $22.70 · Sale (S): 23,648 @ $22.70 · Sale (S): 13,738 @ $22.70EDGAR
2024-01-254Disc Medicine, Inc. (IRON)
jointly with Atlas Venture Fund X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
Sale (S): 47,500 @ $67.65 · Sale (S): 82,500 @ $67.65 · Sale (S): 20,000 @ $67.65EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1885327 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →